Norges Bank
NTLA icon

Norges Bank’s Intellia Therapeutics NTLA Stock Holding History

Norges Bank’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-56,939
Closed -$534K – 1034
2025
Q2 		$534K Buy
+56,939
New +$468K ﹤0.01% 1621
2025
Q1 		– Sell
-30,010
Closed -$350K – 1816
2024
Q4 		$350K Sell
30,010
-15,751
-34% -$246K ﹤0.01% 1809
2024
Q3 		$940K Sell
45,761
-194,654
-81% -$4.49M ﹤0.01% 1736
2024
Q2 		$5.38M Sell
240,415
-373,736
-61% -$8.9M ﹤0.01% 1544
2024
Q1 		$16.9M Buy
614,151
+77,979
+15% +$2.17M ﹤0.01% 1311
2023
Q4 		$16.3M Sell
536,172
-215,996
-29% -$6.21M ﹤0.01% 1329
2023
Q3 		$23.8M Hold
752,168
– – ﹤0.01% 1162
2023
Q2 		$30.7M Buy
752,168
+62,846
+9% +$2.55M 0.01% 1077
2023
Q1 		$25.7M Sell
689,322
-167,956
-20% -$6.59M 0.01% 1161
2022
Q4 		$29.9M Buy
857,278
+194,959
+29% +$9.27M 0.01% 1078
2022
Q3 		$37.1M Buy
662,319
+55,946
+9% +$3.47M 0.01% 892
2022
Q2 		$31.4M Buy
606,373
+105,566
+21% +$5.36M 0.01% 1008
2022
Q1 		$36.4M Buy
500,807
+59,047
+13% +$5M 0.01% 1054
2021
Q4 		$52.2M Sell
441,760
-170,376
-28% -$21.3M 0.01% 915
2021
Q3 		$82.1M Buy
612,136
+197,417
+48% +$29.9M 0.02% 696
2021
Q2 		$67.1M Sell
414,719
-73,917
-15% -$5.76M 0.01% 806
2021
Q1 		$39.2M Buy
+488,636
New +$32.8M 0.01% 1117
2020
Q3 		– Sell
-15,000
Closed -$315K – 2151
2020
Q2 		$315K Buy
+15,000
New +$255K ﹤0.01% 2061
2017
Q1 		– Sell
-67,571
Closed -$886K – 2167
2016
Q4 		$886K Buy
+67,571
New +$1.02M ﹤0.01% 2068

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank's NTLA Position: Q3 2025 in Review

Norges Bank sold out of Intellia Therapeutics (NTLA) in Q3 2025, closing a stake of 56,939 shares — an estimated $534K sold.

Norges Bank first reported a position in NTLA in Q4 2016 and held it in 19 quarters. The position peaked at $82.1M in Q3 2021. 282 funds tracked by Wall St. Rank hold NTLA as of Q3 2025.

  • Norges Bank reported no remaining Intellia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Norges Bank sold 56,939 Intellia Therapeutics shares in Q3 2025, an estimated $534K.
  • Norges Bank first reported a position in Intellia Therapeutics in Q4 2016 and held it in 19 quarters.
  • Norges Bank's Intellia Therapeutics position peaked at $82.1M in Q3 2021.
  • 282 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2025.

Based on Norges Bank's 13F filing for Q3 2025.